November 28, 2013: BioAegis Therapeutics Completes Engineering Run of High-Yield Recombinant Plasma Gelsolin
Company to enter Full-Scale cGMP Production for Clinical Trials BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – March 4, 2013) BioAegis Therapeutics announced today it has completed its engineering manufacturing run and is preparing to launch its manufacture of clinical supplies. The campaign to produce recombinant protein in E. coli was successful and generated higher …